IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0791313
(2013-03-08)
|
등록번호 |
US-8586030
(2013-11-19)
|
발명자
/ 주소 |
- Hsia, Sung Lan
- Narain, Niven Rajin
- Li, Jie
- Russell, Kathryn J.
- Woan, Karrune V.
- Persaud, Indushekhar
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
2 인용 특허 :
106 |
초록
▼
Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation o
Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.
대표청구항
▼
1. A method of treating a pancreatic tumor in a human subject comprising intravenously administering to the subject a composition comprising 1% to 20% w/w of Coenzyme Q10 in an amount effective and for a sufficient time to slow the growth of the pancreatic tumor, thereby treating the pancreatic tumo
1. A method of treating a pancreatic tumor in a human subject comprising intravenously administering to the subject a composition comprising 1% to 20% w/w of Coenzyme Q10 in an amount effective and for a sufficient time to slow the growth of the pancreatic tumor, thereby treating the pancreatic tumor in the subject. 2. The method of claim 1, wherein the composition comprises 1% to 10% w/w of Coenzyme Q10. 3. The method of claim 1, wherein the composition comprises 1% to 5% w/w of Coenzyme Q10. 4. The method of claim 1, wherein the Coenzyme Q10 composition is administered with an additional anti-cancer agent. 5. The method of claim 1, comprising intravenously administering Coenzyme Q10 by continuous infusion. 6. The method of claim 4, wherein the additional anti-cancer agent is co-administered with the composition comprising Coenzyme Q10 to the subject. 7. The method of claim 4, wherein administration of the additional anti-cancer agent precedes administration of the composition comprising Coenzyme Q10 to the subject. 8. The method of claim 4, wherein administration of the additional anti-cancer agent follows administration of the composition comprising Coenzyme Q10 to the subject. 9. The method of claim 4, wherein the additional anti-cancer agent is an anti-angiogenic agent. 10. The method of claim 4, wherein the additional anti-cancer agent is a chemotherapeutic agent. 11. The method of claim 10, wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, taxanes, busulfan, methotrexate, daunorubicin, doxorubicin, melphalan, cladribine, vincristine, vinblastine, chlorambucil, tamoxifen, taxol, camptothecin, actinomycin-D, mitomycin C, combretastatin, cisplatin, etoposide, verapamil, podophyllotoxin, and 5-fluorouracil. 12. The method of claim 11, wherein the taxane is paclitaxel or docetaxel. 13. The method of claim 1, wherein treating the pancreatic tumor comprises inducing apoptosis in a pancreatic tumor cell.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.